Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms |
Target |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MSLN inhibitors(Mesothelin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseIND Application |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | IND Application | CN | 29 Dec 2022 | |
Mesothelioma | IND Application | CN | 29 Dec 2022 | |
Ovarian Cancer | IND Application | CN | 29 Dec 2022 |